ArticleAnnals of surgical treatment and research2026
Prediction of microvascular invasion and post-resection prognosis using ADV, AFP-PIVKA-II, and MoRAL scores in hepatocellular carcinoma patients: an international multicenter cohort study with 9,061 patients.
Article in Annals of surgical treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prediction of Post-Resection Prognosis of HCC According to AFP-PIVKA-II (AP) Score as a Simplified Biomarker of ADV Score: A Validation Analysis Using Korea Liver Cancer Registry Database.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Microvascular invasion (MVI) is a well-known pathological prognostic factor in hepatocellular carcinoma (HCC). This study aimed to predict MVI and to assess post-resection prognosis using the ADV (multiplication of AFP, des-γ-carboxyprothrombin-also known as proteins induced by vitamin K absence or antagonist-II [PIVKA-II], and tumor volume), AP (multiplication of AFP and PIVKA-II), and MoRAL (model to predict tumor recurrence [TR] after liver transplantation) scores. Methods: This international multicenter study included 9,061 patients who underwent hepatic resection for solitary HCC measuring 1.0-10 cm from 2010 to 2017 at ten Korean centers and 73 Japanese centers, and were followed up until 2020. Results: The receiver operating characteristic (ROC) area under the curve (AUC) for diagnosis of MVI was 0.734 for the ADV score at 4.7log, 0.684 for the AP score at 3.7log, and 0.705 for the MoRAL score at 162.0. The ADV score exhibited the strongest predictive ability for MVI. The ROC AUC for actuarial 5-year TR was 0.586 for the ADV score, 0.583 for the AP score, and 0.586 for the MoRAL score, demonstrating similar prognostication efficacy. The hazard ratios for TR and overall survival demonstrated strong, stepwise positive correlations with increases in both the ADV and AP scores, but not the MoRAL score. Conclusions: The ADV score is a superior integrated biomarker for predicting post-resection prognosis in patients with HCC, outperforming both the AP and MoRAL scores. The AP score appears to be a simplified alternative to the ADV score, particularly in cases of small HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.